| 2022/05/19 17:31:37 | |
|---|---|
| Price | |
| 656.9547 USD | |
| Difference | 8.27% (50.16) |
General attributes
| ISIN | US75886F1075 |
| Symbol | REGN |
| Exchange | London Stock Exchange |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 66,189 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 656.9547 USD |
| High | 656.9547 USD |
| Low | 656.9547 USD |
| Close (prev. day) | 606.79 USD |
| VWAP | 656.95467 USD |
| Volume (pcs) | 303 |
| Trading volume | 177,377.76 |
| Number of trades | 4 |
| Last size | 270 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: REGENERON PHARMACEUTICALS INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2022/05/04 |
|
Global Equity Ratings |
|
| 2022/04/27 |
|
Global Equity Ratings |
|
| 2022/04/14 |
|
Global Equity Ratings |
|
| 2022/03/29 |
|
Global Equity Ratings |
|
| 2022/03/10 |
|
Global Equity Ratings |
|
| 2022/05/19 17:31:37 | |
|---|---|
| Price | |
| 656.9547 USD | |
| Difference | 8.27% (50.16) |
General attributes
| ISIN | US75886F1075 |
| Symbol | REGN |
| Exchange | London Stock Exchange |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 66,189 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 656.9547 USD |
| High | 656.9547 USD |
| Low | 656.9547 USD |
| Close (prev. day) | 606.79 USD |
| VWAP | 656.95467 USD |
| Volume (pcs) | 303 |
| Trading volume | 177,377.76 |
| Number of trades | 4 |
| Last size | 270 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | - | - | - |
| Perf (abs.) | - | - | - |
| Beta | 0.53 | 0.54 | 0.58 |
| Volatility | 7.58 | 6.14 | 19.24 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 131.3909 USD (81) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 205.8059 USD (170) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 125.2118 USD (79) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 113.9338 USD (164) |
| YTD High | date | 732.8600 USD (2022/04/08) |
| YTD Low | date | 603.7300 USD (2022/01/10) |
| 52 Weeks High | date | 732.8600 USD (2022/04/08) |
| 52 Weeks Low | date | 509.2700 USD (2021/06/07) |
All listings for REGENERON PHARMACEUTICALS INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Berlin | 2022/05/20 | 08:01 | 620.90 EUR | 0.00 | 1 |
| Duesseldorf | 2022/05/20 | 18:01 | 620.40 EUR | 0.00 | 9 |
| Frankfurt | 2022/05/20 | 08:10 | 620.20 EUR | 0.00 | 1 |
| Hamburg | 2022/05/20 | 08:01 | 618.40 EUR | 0.00 | 1 |
| Hanover | 2022/05/20 | 08:01 | 618.40 EUR | 0.00 | 1 |
| London Stock Exchange | 2022/05/19 | 17:31 | 656.9547 USD | 0.18 | 4 |
| Munich | 2022/05/20 | 08:01 | 625.90 EUR | 0.00 | 1 |
| Nasdaq | 2022/05/20 | 22:00 | 661.14 USD | 357.70 | 26,282 |
| Stuttgart | 2022/05/20 | 12:51 | 624.40 EUR | 0.01 | 9 |
| Tradegate | 2022/05/20 | 22:26 | 626.30 EUR | 0.06 | 6 |
| Vienna Stock Exchange | 2022/05/20 | 17:32 | 621.30 EUR | 0.00 | 2 |
| Xetra | 2022/05/20 | 17:35 | 620.80 EUR | 0.01 | 3 |
Company Logo
Contact Details
| REGENERON PHARMACEUTICALS INC. |
| - - |
| 777 Old Saw Mill River Road - 10591-6707 Tarrytown |
| Telefon: 1-914-847-7000 |
| Fax: - |
| E-mail: - |
PDF Downloads
| Company report: REGENERON PHARMACEUTICALS INC. | |
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY. |
Members of Management Board
| P. Vagelos | Chairman of Board of Directors |
| Bonnie Bassler | Member of Board of Directors |
| George Yancopoulos | Member of Board of Directors |
| Huda Zoghbi | Member of Board of Directors |
| Joseph Goldstein | Member of Board of Directors |
| Marc Tessier-Lavigne | Member of Board of Directors |
| Michael Brown | Member of Board of Directors |
| N. Coles | Member of Board of Directors |
| Arthur Ryan | Member of Board of Directors |
| Christine Poon | Member of Board of Directors |
| George Sing | Member of Board of Directors |
| Leonard Schleifer | Chairman of Managing Board |
| Alan Shuldiner | Member of Executive Committee |
| Andrew Murphy | Member of Executive Committee |
| David Weinreich | Member of Executive Committee |
| Kerry Reinertsen | Member of Executive Committee |
| Ned Braunstein | Member of Executive Committee |
| Neil Stahl | Member of Executive Committee |
| Beth Holly | Member of Executive Committee |
| Bob McCowan | Member of Executive Committee |
| Christopher Fenimore | Member of Executive Committee |
| Daniel van Plew | Member of Executive Committee |
| Gerald Underwood | Member of Executive Committee |
| Joseph LaRosa | Member of Executive Committee |
| Marion McCourt | Member of Executive Committee |